DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020
12 nov. 2020 12h30 HE
|
Deinove
DEINOVE selected for a presentation at the C Diff Foundation annual Conference 2020 ·Yannick Pletan to present the DNV3837 mechanism of action, key features of the antibiotic candidate and the...
DNV3837 antibiotic candidate: the Phase II trial continues in the US
15 juil. 2020 12h30 HE
|
Deinove
DNV3837 antibiotic candidate: the Phase II trial continues in the United States, despite a disrupted context due to the COVID-19 outbreak DEINOVE (Euronext Growth Paris: ALDEI), a French biotech...
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections
27 janv. 2020 01h30 HE
|
Deinove
Enrolment of first patient in Phase II trial testing DNV3837 in Clostridioides difficile infections The Phase II clinical trial aims to evaluate the efficacy, safety and pharmacokinetics of DNV3837...
DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837
16 mai 2019 12h30 HE
|
Deinove
DEINOVE is now ready to start Phase II clinical trial for its antibiotic compound DNV3837 Having reached a sufficient number of clinical centers, Phase II clinical trial testing the antibiotic...
DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé
31 janv. 2019 02h00 HE
|
Deinove
DEINOVE prépare l’entrée en Phase II du DNV3837 dans les infections à Clostridium difficile avec un partenaire-clé Le design de l’essai a été optimisé pour maximiser les chances de démontrer...
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner
31 janv. 2019 02h00 HE
|
Deinove
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner The test design has been improved for a better assessment of DNV3837 effectiveness in...